newsfilter
← Latest News
Business Wire·

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Enveric expects to file Investigational New Drug application for EB-003 in early 2026 Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic